AEON vs. PRQR, SCPH, GOSS, GLSI, CAPR, CRVO, TELO, ACET, IVA, and SKYE
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include ProQR Therapeutics (PRQR), scPharmaceuticals (SCPH), Gossamer Bio (GOSS), Greenwich LifeSciences (GLSI), Capricor Therapeutics (CAPR), CervoMed (CRVO), Telomir Pharmaceuticals (TELO), Adicet Bio (ACET), Inventiva (IVA), and Skye Bioscience (SKYE). These companies are all part of the "medical" sector.
AEON Biopharma (NASDAQ:AEON) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.
AEON Biopharma presently has a consensus price target of $18.00, suggesting a potential upside of 351.13%. ProQR Therapeutics has a consensus price target of $3.60, suggesting a potential upside of 82.74%. Given AEON Biopharma's higher possible upside, research analysts plainly believe AEON Biopharma is more favorable than ProQR Therapeutics.
AEON Biopharma has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
ProQR Therapeutics received 322 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 61.95% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher revenue and earnings than AEON Biopharma.
AEON Biopharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -431.65%. AEON Biopharma's return on equity of 0.00% beat ProQR Therapeutics' return on equity.
22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 20.0% of AEON Biopharma shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, ProQR Therapeutics had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for ProQR Therapeutics and 0 mentions for AEON Biopharma. ProQR Therapeutics' average media sentiment score of 0.16 beat AEON Biopharma's score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media.
Summary
ProQR Therapeutics beats AEON Biopharma on 8 of the 14 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
